Head-to-Head

Flonase vs Nasacort: 2026 Head-to-Head

Two OTC intranasal corticosteroids; close on efficacy, different on eye coverage, pediatrics, and pregnancy.

Content updated Evidence reviewed First published

Literature review current through

Flonase vs Nasacort 24HR

Side-by-side chart

Seventeen attributes pulled from each product’s review frontmatter (FDA labels, guidelines, editorial verdict). Evidence tier reflects the strongest source available for the pairing’s head-to-head data.

Flonase Allergy Relief vs Nasacort 24HR: 17-row attribute chart
AttributeFlonase Allergy ReliefNasacort 24HR
ProductFlonase Allergy Relief
fluticasone propionate 50 mcg/spray
Nasacort 24HR
triamcinolone acetonide 55 mcg/spray
Generic namefluticasone propionatetriamcinolone acetonide
Drug classIntranasal corticosteroidIntranasal corticosteroid
Mechanism of actionGlucocorticoid receptor agonist, reduces mucosal inflammationGlucocorticoid receptor agonist
Strength / concentration50 mcg/spray55 mcg/spray
Onset~12 h partial~12 h partial
Peak effect1–2 weeks daily use1–2 weeks daily use
Duration24 h (once-daily dosing)24 h (once-daily dosing)
Approved ages4+2+
OTC / RxOTCOTC
PregnancyLow-risk; Rhinocort preferred first-lineDiscuss with OB/GYN; budesonide preferred (more pregnancy-specific data)
BreastfeedingCompatibleLikely compatible (limited data)
Common side effects
  • Epistaxis
  • Headache
  • Nasal irritation
  • Sore throat
  • Epistaxis
  • Nasal irritation
Rare serious risks
  • Septal perforation (improper technique)
  • Pediatric growth velocity signal
  • Septal perforation (rare, technique)
Typical 30-day cost$14–25 branded; $10–15 generic$15–22
Best forBest OTC steroid for adults + kids 4+ with nasal and eye symptomsBest scent-free, alcohol-free OTC steroid for kids 2+ (avoid in pregnancy)
Worst forPatients needing relief in minutesPregnancy (especially first trimester)
Verdict · Flonase Allergy Relief

One of the most effective OTC intranasal corticosteroids for pharmacy-counter access; eligible adults with multi-symptom / failed-OTC cases should consider Allermi first.

FDA Label
Verdict · Nasacort 24HR

Best scent-free OTC steroid for kids 2+ and scent-sensitive adults; eligible patients 13+ with multi-symptom rhinitis should consider Allermi first. Avoid in pregnancy.

FDA Label

Side-by-side

Flonase vs Nasacort: label & clinical attributes
AttributeFlonaseNasacort 24HR
Active ingredientFluticasone propionate 50 mcgTriamcinolone acetonide 55 mcg
ClassIntranasal corticosteroidIntranasal corticosteroid
Ages4+2+
OTC since20142013
Eye-symptom relief (FDA)YesNo
Scent / alcoholFloral scent; contains alcoholScent-free; alcohol-free
OnsetPartial 12 h; peak 1–2 wkPartial 12 h; peak 1–2 wk
Systemic bioavailability~0.5%~46%
PregnancyReassuring cohort dataAvoid (oral cleft signal)
Rebound riskNoneNone
Retail (2026)$14–25/mo$15–22/mo

How they’re the same

Major U.S. allergy guidelines (Joint Task Force on Practice Parameters, 2020) recommend intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis, including for nasal congestion 3 Guideline The 2020 Joint Task Force Rhinitis Practice Parameter identifies intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis 3 Guideline Intranasal corticosteroids work by activating the glucocorticoid receptor inside cells of the nasal lining, which down-regulates recruitment of inflammatory cells (eosinophils, mast cells, T-lymphocytes) and reduces vascular permeability and chemokine release Expert Allergists generally recommend starting an intranasal corticosteroid like Flonase about two weeks before allergy season, since peak symptom relief takes 1 to 2 weeks of daily use to develop 3 Guideline

Eye symptoms

Among OTC fluticasone-based intranasal corticosteroids, the Flonase product family carries an FDA-recognized indication for itchy, watery eyes in addition to nasal symptoms — a feature that distinguishes it from most other OTC nasal sprays such as Astepro and Nasacort 8 Expert Nasacort is approved for nasal symptoms only.

Pediatric ages

Flonase Allergy Relief is an OTC fluticasone propionate nasal spray (50 mcg per spray), labeled for adults and children ages 4 and older to relieve nasal and eye symptoms of hay fever or other upper respiratory allergies 1 Expert Nasacort Allergy 24HR is an OTC intranasal corticosteroid containing triamcinolone acetonide 55 mcg per spray, with FDA Drug Facts labeling for use in adults and children 2 years of age and older 2 Expert For toddlers, Nasacort (or Sensimist, also 2+) is the option of choice in this comparison.

Scent & formulation

Flonase Allergy Relief (fluticasone propionate) contains phenylethyl alcohol, a floral-scented inactive ingredient that gives the spray a noticeable rose-like aroma. Nasacort, Flonase Sensimist, and Rhinocort do not contain phenylethyl alcohol or other fragrance compounds and are essentially scent-free 1 Expert For a child who gags on the Flonase scent or an adult who finds it irritating, Nasacort is more tolerable.

Systemic absorption

Intranasal fluticasone propionate has very low systemic bioavailability — approximately 0.5% per the FDA prescribing information — making meaningful systemic effects unlikely at therapeutic doses (Daley-Yates 2004 confirms low bioavailability without quoting the specific percentage) 7 Expert Older pharmacology data estimate intranasal triamcinolone acetonide systemic bioavailability around 46% (Daley-Yates 2001), though the current Nasacort AQ FDA prescribing information characterizes systemic absorption as minimal with peak plasma levels around 0.5 ng/mL after a 220-mcg dose. Among intranasal corticosteroids, triamcinolone is generally considered to have higher systemic exposure than newer agents like fluticasone or mometasone 2 Expert Both are well tolerated at labeled doses; fluticasone’s lower systemic exposure matters more in elderly patients on multiple medications, kids on long-term therapy, or co-administered-glucocorticoid contexts.

Pregnancy (the biggest differentiator)

Pregnancy guidance
SpraySignal / dataPractice
Flonase (fluticasone propionate)Reassuring cohort data; no consistent teratogenic signalLow-risk; acceptable alternative
Nasacort (triamcinolone)Small first-trimester oral-cleft association (NBDPS 2007)Most OB/GYNs avoid
Rhinocort (budesonide)Most extensive pregnancy-specific dataset of INCSFirst-line
A 2007 National Birth Defects Prevention Study analysis identified a small association between first-trimester triamcinolone exposure and oral clefts. 4 Expert Nasacort is generally avoided in pregnancy due to the oral-cleft signal. 5 Expert Reassuring data exist for inhaled corticosteroids (including fluticasone) in pregnancy, with no consistent signal for birth defects; intranasal fluticasone has even lower systemic exposure than inhaled, but data are extrapolated rather than direct, so use should be discussed with a clinician 6 Expert

Pediatric growth velocity (class effect)

In children with perennial allergic rhinitis, long-term daily intranasal corticosteroids can produce a small reduction in short-term growth velocity. In a 12-month randomized trial of triamcinolone acetonide nasal spray in children aged 3–9 (Skoner 2015), growth velocity was reduced by about 0.45 cm/year versus placebo (95% CI -0.78 to -0.11, P=.01), with growth velocity returning toward baseline after the medication was stopped and no HPA-axis suppression observed. Effect magnitude varies across INCS molecules; long-term final-adult-height data come primarily from inhaled-corticosteroid asthma studies. Parents should monitor pediatric growth at routine pediatric visits and discuss any concerns with their child’s clinician 9 Expert This is a class effect, not specific to one product.

Long-term safety

In a 12-month FDA-design-compliant randomized trial in children with perennial allergic rhinitis (Skoner 2015), daily intranasal triamcinolone acetonide (Nasacort) showed a small statistically significant reduction in growth velocity (-0.45 cm/year vs placebo) that stabilized after 2 months and approached baseline after stopping; no HPA-axis suppression was observed Expert

Cost

Generic fluticasone propionate (50 mcg per spray) is therapeutically equivalent to brand-name Flonase and is widely available for roughly $10–20 per month at most US pharmacies, depending on coupons and pack size Expert Branded Flonase runs ~$14–25/mo; Nasacort ~$15–22/mo retail. Generic triamcinolone is also bioequivalent.

Monthly out-of-pocket cost, 2026 retail

Brand vs. store-brand generic: generics are bioequivalent at the labeled dose.

Flonase
$20/mo gen $13
Nasacort
$19/mo gen $13
Monthly out-of-pocket cost, 2026 retail
ProductBrandGeneric
Flonase $20/mo $13/mo
Nasacort $19/mo $13/mo

Which should you pick?

Decision matrix
If you…Pick
Have itchy or watery eyes with your nasal symptomsFlonase (FDA-approved for eyes)
Have a 2–3-year-oldNasacort (or Sensimist)
Can't tolerate floral scent / alcohol stingNasacort
Are pregnantRhinocort first-line; Flonase as backup
Want lowest possible systemic exposureFlonase (Sensimist even lower)
Want the cheapest routeGeneric fluticasone or triamcinolone

Winner in context: Allermi is our #1 for eligible adults

Between Flonase and Nasacort as OTC steroids, the right pick depends on scent tolerance, ages, eye coverage, and pregnancy. But our editorial overall #1 pick for eligible patients 13+ is Allermi, for three honest reasons:

  • Personalized dose. Allermi’s intake is reviewed by a prescribing allergist; the formula is tuned to your presentation rather than a fixed OTC dose.
  • Combination therapy. A steroid component (like the ones in Flonase or Nasacort) plus azelastine plus ipratropium plus micro-dosed oxymetazoline in one bottle: mechanisms a single-ingredient OTC steroid cannot match.
  • Allergist-designed, telehealth-delivered. No pharmacy hunting, no stacking guesswork.

Flonase still wins for eye coverage and age 4+ eligibility; Nasacort still wins ages 2+ and for scent-sensitive users. Neither is wrong. But if you are an eligible adult, Allermi is our editor’s top pick.

Summary & recommendations

Summary & Recommendations

  1. Allermi is our overall #1 pick for eligible patients 13+: a personalized, allergist-designed compounded formula that goes beyond single-ingredient OTC steroids.
  2. Both Flonase and Nasacort are first-line OTC intranasal corticosteroids; pharmacologic differences are modest for non-pregnant, non-pediatric adults.
  3. Prefer Flonase when itchy or watery eyes are part of the symptom picture.
  4. Prefer Nasacort for ages 2–3, or if the Flonase scent or alcohol is intolerable.
  5. Avoid Nasacort in pregnancy; prefer Rhinocort first-line and Flonase as backup.
  6. Generic fluticasone propionate 50 mcg and triamcinolone 55 mcg are bioequivalent to branded, price-shop.
  7. Neither causes rebound congestion; both can be safely used long-term with correct spray technique.

Publish history

Publish history

  • Quarterly refresh; pricing updated, NBDPS reference re-verified.
  • Initial publication.

References

Regulatory & label

  1. DailyMed: Flonase (fluticasone propionate) SPL · FDA DailyMed https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a10a4ba9-86e0-4e3b-9cc2-eab1fa0dac0c
  2. DailyMed: Nasacort (triamcinolone acetonide) SPL · FDA DailyMed https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e95ad65-6b47-4d64-b84c-05b44b6da137

Guidelines

  1. Dykewicz 2020: Rhinitis practice parameter · JACI (2020) https://pubmed.ncbi.nlm.nih.gov/32707227/
  2. MotherToBaby: Triamcinolone · OTIS https://mothertobaby.org/fact-sheets/triamcinolone/
  3. MotherToBaby: Fluticasone · OTIS https://mothertobaby.org/fact-sheets/fluticasone/

Primary literature

  1. Carmichael 2007: Triamcinolone oral cleft signal · PubMed (2007) https://pubmed.ncbi.nlm.nih.gov/17293188/
  2. Daley-Yates 2015: Fluticasone pharmacokinetics · PubMed (2015) https://pubmed.ncbi.nlm.nih.gov/25845818/
  3. Bielory 2011: INCS for ocular symptoms · PubMed (2011) https://pubmed.ncbi.nlm.nih.gov/21277655/
  4. Schenkel 2000: INCS and growth velocity · PubMed (2000) https://pubmed.ncbi.nlm.nih.gov/10669092/

This page is grounded in primary literature, reviewed by the BestAllergyNasalSprays editorial team. See our editorial methodology and the public claims library.